Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior

Depression and Anxiety

Volumn 6, Issue 1, 1997, Pages 31-39

  Wernicke, Joachim F ^a   Sayler, Mary E ^b   Koke, Stephanie C ^b   Pearson, Donna K ^b   Tollefson, Gary D ^b  

^a ELLYN Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Drug therapy; Psychiatry; Psychopharmacology

Indexed keywords

AMITRIPTYLINE; ANXIOLYTIC AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PSYCHOTROPIC AGENT; SEDATIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUICIDE;

EID: 0031426673     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(1997)6:1<31::AID-DA5>3.0.CO;2-8     Document Type: Article

References (18)

1. American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd ed.). Washington, DC: American Psychiatric Association.
2. Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN (1991) Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. Br Med J 503:685-692.
3. Cleary MA, Guy W (1975) Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1:115-120.
4. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
5. Fluoxetine Bulimia Nervosa Collaborative Study Group (1992) Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatr 49:139-147.
6. Greenland S, Robins JM (1985) Estimation of a common effect parameter from sparse follow-up data. Biometrics 41:55-68.
7. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
8. Rothschild AJ, Locke CA (1991) Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatr 52:491-493.
9. SAS Institute (1990) User's Guide, Version 6. Cary, NC: SAS Institute, Inc.
10. Sato T (1989) On the variance estimator for the Mantel-Haenszel risk difference. Biometrics 45:1323-1324.
11. Stark P, Hardison CD (1985) A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatr 46:53-58.
12. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D (1995) Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 332:1529-1534.
13. Tollefson GD, Rampey AH Jr, Beasley CM Jr, Enas GG, Potvin JM (1994a) Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 14:163-169.
14. Tollefson GD, Rampey AHJ, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA (1994b) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatr 51:559-567.
15. Tollefson GD, Sayler MS (1997) Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double-blind controlled trials with fluoxetine. Depress Anx 4:294-311.
16. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL (1987) Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 23:164-168.
17. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M (1988) Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24:183-188.
18. Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T (1992) Fluoxetine, akathisia, and suicidality: Is there a causal connection? [letter]. Arch Gen Psychiatr 49: 580-581.